Send article: Viamet Pharmaceutical, a Research Triangle park biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, closed a $4 million Series A financing round

BT Catalyst, July-August, 2007  

Recipient's email

Your name

Your email

Comments